November 12, 2009. Those of us who are here know that our concerns are shared by many other public health, patient, and consumer organizations. However, most do not have the staff or resources to set aside two days of unscheduled time for a meeting, especially non-reimbursed time, and especially in the middle of the health care reform negotiations.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to Dr. Margaret Hamburg, FDA Commissioner, Urging that Immediate Action Be Brought to Appropriately Regulate Tanning Devices
November 5, 2009. Members of the Patient and Consumer Coalition urge your immediate attention to appropriately regulate tanning devices. As you know, currently, tanning devices are Class I devices (the same as bandages), which is the U.S. Food and Drug Administration’s (FDA) lowest risk device class and does not require comprehensive safety data.
Read More »Letter to Principal Deputy Commissioner Sharfstein Expressing Concerns About the Food and Drug Administration Amendments Act (FDAAA)
October 6, 2009. In September 2007, the Food and Drug Administration Amendments Act (FDAAA) was signed into law.
Read More »NCHR Comment on “Statement of Policy: Testing of Component Parts With Respect to Section 108 of the Consumer Product Safety Improvement Act”
September 16, 2009. Given that phthalate concentrations can be diluted in large toys, we agree with Commission staff that testing phthalate content as a percentage of the entire toy or child care article is less effective than testing materials and component parts that may contain phthalates.
Read More »NCHR Comment to the FDA on “Medical Devices: Ophthalmic Devices; Laser-Assisted In Situ Keratomileusis (LASIK) Devices; Establishing a Docket”
September 14, 2009. The National Research Center for Women & Families submits the following comments regarding the laser-assisted in situ keratomileusis (LASIK) and the post market experience associated with the use of LASIK devices.
Read More »